PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

Cowen Annual Health Care Conference on Monday, March 1, 2021 at 1:20 p.m. EST

Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. EST

The live webcasts can be accessed at the company’s investors page at investor.pacificbiosciences.com. The replays will be available for at least 30 days following the presentation.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information please visit and follow .

Contacts

Investors:

Todd Friedman

650.521.8450



EN
26/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

PacBio Grants Equity Incentive Award to New Employee

PacBio Grants Equity Incentive Award to New Employee MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”...

 PRESS RELEASE

PacBio to Participate in the BofA Securities 2022 Healthcare Conferenc...

PacBio to Participate in the BofA Securities 2022 Healthcare Conference MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time. The live webcast can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the presentation. About PacBio PacBi...

 PRESS RELEASE

PacBio Announces First Quarter 2022 Financial Results

PacBio Announces First Quarter 2022 Financial Results MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.Delivered a record 50 Sequel II/IIe systems during the quarter compared to 41 Sequel II/IIe systems placed in the prior year quarter.Installed base of 424 Sequel II/IIe systems as of March 31, 2022, compared with 244 as of March 31, 2021.Instrument revenue of $15.6 million, c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch